SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm CyTOF technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell (MSC) therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy.
Results of the study, conducted by researchers in China, have been published in Aging and Disease.1
We used a 36-marker CyTOF panel to generate a broad immune profile of each patients peripheral blood before and after transplantation, said Wenjing Wang, PhD, Associate Professor at Beijing Hepatology Research Institute, Youan Hospital. Mass cytometry allowed us to look at all immune populations of interest in a single tube of peripheral blood mononuclear cells, enabling us to use less sample and to simplify our workflow and analysis.
The study, which evaluated clinical outcomes as well as changes in inflammatory and immune function for 14 days in seven patients with COVID-19 pneumonia, indicated that intravenous transplantation of MSCs was a safe and effective treatment for patients with COVID-19 pneumonia, including for those in severe condition.
Pulmonary function and symptoms of these seven patients were significantly improved within two days of MSC transplantation. Three of the patients, including one classified as severe, recovered and were discharged 10 days after treatment.
CyTOF analysis found that MSC treatment of severe cases led to disappearance in three to six days of overactivated cytokine-secreting immune cells and increases in regulatory T and dendritic cells. Importantly, there was a dramatic increase in a population of CD14+CD11c+CD11bmidregulatory dendritic cells, which may have helped to tamp down the cytokine storm associated with COVID-19 respiratory disease. Separate analysis of patient serum found significant reduction in levels of TNF-, a potent inflammatory cytokine, while IL-10, an anti-inflammatory cytokine, increased in the MSC treatment group compared to the placebo control group.
This level of new and valuable treatment research based on broad-based immune profiling is an important front in the COVID-19 fight, said Chris Linthwaite, President and CEO of Fluidigm. Fluidigm is actively engaged with many researchers in government and medical institutions who are addressing the COVID-19 pandemic from the perspectives of both immune profiling and virus detection and testing, and this study underscores the critical role that our technologies are playing in the global response to the outbreak.
In addition to our instruments, our assays and analysis software are increasingly the focus of customers in the global research community exploring immune profiling of COVID-19 infected populations. Our Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter analysis software are a solution for labs seeking an easily deployed, fixed panel that can incorporate novel exploratory markers as well as standard markers, Linthwaite said.
We are inspired by this opportunity to provide meaningful tools in efforts to develop innovative solutions to this rapidly evolving pandemic.
About FluidigmFluidigm(FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.
Fluidigm, theFluidigmlogo, CyTOF, Direct, Immune Profiling Assay, Maxpar, and Pathsetter are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Story continues
Forward-Looking Statements for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the implementation of Fluidigm microfluidics technology and products by third parties and the anticipated benefits of, and applications and demand for, such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affectingFluidigmbusiness and operating results is contained in Fluidigms Annual Report on Form 10-K for the year endedDecember 31, 2019, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Fluidigmdisclaims any obligation to update these forward-looking statements except as may be required by law.
1 Leng, Z., Zhu, R., Hou, W. et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and Disease 11 (2020): 216228.
Contacts:
Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com
Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com
Go here to see the original:
- Skin-care founder Angela Caglia on the stem cell technology that created 437% sales growth: 'It's transformed the business' - Glossy - November 8th, 2024
- Substantial Overview on Mesenchymal Stem Cell Biological and Physical ... - November 8th, 2024
- Regenerative Medical Technology Group Announces the Opening of New Clinic in Dubai on November 23 - Newswire - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - StockTitan - November 8th, 2024
- Stem cell science is dominating the luxury skin-care market as human-derived ingredients become less taboo - Glossy - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - The Manila Times - November 8th, 2024
- SMART researchers develop a method to enhance effectiveness of cartilage repair therapy - MIT News - October 25th, 2024
- Biological functions of mesenchymal stem cells and clinical ... - October 24th, 2024
- Chemical-defined medium supporting the expansion of human mesenchymal ... - October 24th, 2024
- Mesenchymal Stem Cells: Time to Change the Name! - PMC - October 24th, 2024
- Insights into the molecular characteristics of embryonic cranial neural crest cells and their derived mesenchymal cell pools - Nature.com - October 20th, 2024
- Acquisition of durable insulin-producing cells from human adipose tissue-derived mesenchymal stem cells as a foundation for cell- based therapy of... - October 20th, 2024
- Sources and Clinical Applications of Mesenchymal Stem Cells - October 20th, 2024
- Effects of inorganic phosphate on stem cells isolated from human exfoliated deciduous teeth - Nature.com - October 18th, 2024
- Researchers pioneer novel method to enhance effectiveness of MSC therapy for cartilage repair - Medical Xpress - October 18th, 2024
- Healing begins with research: Promising development program on stem cells in rare diseases - Yahoo! Voices - October 15th, 2024
- Unveiling the Immunomodulatory and regenerative potential of iPSC-derived mesenchymal stromal cells and their extracellular vesicles - Nature.com - October 15th, 2024
- Manufactured stem cells could help to treat blood cancers in the future - Health Tech World - October 14th, 2024
- miR-16a-5p antagonizes FGF-2 in ligamentogenic differentiation of MSC: a new therapeutic perspective for tendon regeneration - Nature.com - October 11th, 2024
- Effects, methods and limits of the cryopreservation on mesenchymal stem ... - October 10th, 2024
- ALKBH5 regulates etoposide-induced cellular senescence and osteogenic differentiation in osteoporosis through mediating the m6A modification of VDAC3... - October 10th, 2024
- Mesenchymal stromal cells: Biology of adult mesenchymal stem cells ... - October 8th, 2024
- Clever Robotic clothing and manufactured stem cells to treat cancer among revolutionary healthcare tech projects - University of Strathclyde - October 8th, 2024
- Dr. Peisong Gao, MD, PhD - Hopkins Medicine - October 4th, 2024
- Research to Boost Bone Formation Informs Orthopaedic Treatments - October 4th, 2024
- Garza Laboratory - Johns Hopkins Medicine - October 4th, 2024
- Stem Cell Treatment Promises to Prevent Disease and Slow Aging - Newsweek - September 30th, 2024
- Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells - Journal of Translational... - September 28th, 2024
- A mathematical insight to control the disease psoriasis using mesenchymal stem cell transplantation with a biologic inhibitor - Nature.com - September 20th, 2024
- Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production -... - September 20th, 2024
- Implication of CXCR2-Src axis in the angiogenic and osteogenic effects of FP-TEB - Nature.com - September 20th, 2024
- Strategic targeting of miR-183 and -catenin to enhance BMSC stemness in age-related osteoporosis therapy - Nature.com - September 16th, 2024
- The order of green and red LEDs irradiation affects the neural differentiation of human umbilical cord matrix-derived mesenchymal cells - Nature.com - September 14th, 2024
- ENCell and Lucy Biotech Sign a Strategic Alliance and Licensing Agreement for the Next generation Mesenchymal Stem Cell Therapy (EN001) - PR Newswire - September 14th, 2024
- Japanese brand Eternam taps regenerative medicine to develop lip and skin care from umbilical cord-derived stem cell - CosmeticsDesign-Asia.com - September 10th, 2024
- Advances in Tissue Engineering and Its Future in Regenerative Medicine Compared to Traditional Reconstructive Techniques: A Comparative Analysis -... - September 8th, 2024
- Editorial: The future direction toward immunological issues of allo-and xeno-islet transplantation - Frontiers - September 8th, 2024
- Translational potential of mesenchymal stem cells in regenerative ... - September 4th, 2024
- Global microRNA profiling of bone marrow-MSC derived extracellular vesicles identifies miRNAs associated with hematopoietic dysfunction in aplastic... - August 24th, 2024
- A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders - Cureus - August 22nd, 2024
- Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart... - August 22nd, 2024
- Infinite Health Integrative Medicine Center Revolutionizes Regenerative Medicine with Advanced Mesenchymal Signaling Cell Therapy - PR Newswire - August 22nd, 2024
- Stem Cell Therapy Market to Grow at 11.2% CAGR through 2031 - EIN News - August 22nd, 2024
- Immunomodulatory properties of nave and inflammation-informed dental pulp stem cell derived extracellular vesicles - Frontiers - August 20th, 2024
- Exciting advance in stem cell therapy - McGill Newsroom - August 16th, 2024
- Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with... - August 16th, 2024
- Establishment of a stem cell administration imaging method in bleomycin-induced pulmonary fibrosis mouse models - Nature.com - August 16th, 2024
- Editorial: Bringing function to the forefront of cell therapy: how do we demonstrate potency? - Frontiers - August 12th, 2024
- Anti-aging enthusiasts are having stem cell injections in their knees at more than $16K a pop - New York Post - August 10th, 2024
- Exosomes and Equine Health - Horse Sport - August 10th, 2024
- Therapeutic application of mesenchymal stem cell-derived exosomes in skin wound healing - Frontiers - August 6th, 2024
- Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results - August 2nd, 2024
- NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results - August 2nd, 2024
- Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update - August 2nd, 2024
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - August 2nd, 2024
- T2 Biosystems to Attend Upcoming Investor Conferences - August 2nd, 2024
- Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific - August 2nd, 2024
- Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device - August 2nd, 2024
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - August 2nd, 2024
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Stem cell therapy leads to short-term disability reduction in MS - Multiple Sclerosis News Today - July 22nd, 2024
- Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17/Treg balance -... - July 22nd, 2024
- Clene to Present at the Emerging Growth Conference - July 14th, 2024
- Voting Rights and Shares Capital of the Company - July 10th, 2024
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - July 10th, 2024
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 10th, 2024
- Report on Carbios’ liquidity contract with Natixis ODDO BHF - July 10th, 2024
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 10th, 2024
- Activation of cellular antioxidative stress and migration activities by purified components from immortalized stem cells ... - Nature.com - July 5th, 2024
- These 3D model brains with cells from several people are first of their kind - Nature.com - June 30th, 2024
- Introduction to Stem Cells | STEM Cell Information - June 30th, 2024
- Mesenchymal Stromal Cells and Their Secretome: New Therapeutic Perspectives for Skeletal Muscle Regeneration - Frontiers - June 28th, 2024
- Therapeutic potential of small extracellular vesicles derived from mesenchymal stem cells for spinal cord and nerve injury - Frontiers - June 28th, 2024
- Optimizing cell therapy by sorting cells with high extracellular vesicle secretion - Nature.com - June 11th, 2024
- New method for safe and efficient cell transfection developed by researchers - Phys.org - June 5th, 2024
- Predicting the Effectiveness of MSCs for Cartilage Repair - RegMedNet - June 5th, 2024
- Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety ... - June 2nd, 2024
Recent Comments